# Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma

> **NCT04565327** · PHASE2 · TERMINATED · sponsor: **Zhen Wang, MD** · enrollment: 7 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Hyperpolarized Carbon C 13 Pyruvate
- **PROCEDURE:** Magnetic Resonance Imaging (MRI)

## Key facts

- **NCT ID:** NCT04565327
- **Lead sponsor:** Zhen Wang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-14
- **Primary completion:** 2022-11-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04565327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04565327, "Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04565327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*